Study reveals no impact of age on outcome in chronic myeloid leukemia patients treated with imatinib

While the median age at diagnosis for chronic myeloid leukemia (CML) is over 60 years old and incidence increases dramatically with age,limited data are available about the long-term outcome for older patients treated with imatinib, the standard first-line therapy used to treat CML. Results from a study published today in Blood, the Journal of the

Read the whole article on Physorg

More from Physorg